Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails

Clinical Orthopaedics and Related Research

Volumn 472, Issue 9, 2014, Pages 2728-2734

  Egol, Kenneth A ^a,b   Park, Ji Hae ^a   Rosenberg, Zehava Sadka ^c   Peck, Valerie ^d   Tejwani, Nirmal C ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b JAMAICA HOSPITAL MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; BLADE PLATE; BONE GRAFT; BONE RADIOGRAPHY; CLINICAL ARTICLE; COMPRESSION PLATE; CONFERENCE PAPER; CONVALESCENCE; FEMALE; FEMUR FRACTURE; FOLLOW UP; FRACTURE HEALING; FRACTURE NONUNION; HUMAN; INTERLOCKING NAIL; INTRAMEDULLARY NAIL; INTRAMEDULLARY NAILING; LEG PAIN; MALE; MIDDLE AGED; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; ORTHOPEDIC SURGEON; OSTEOPOROSIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHORT MUSCULOSKELETAL FUNCTIONAL ASSESSMENT; TREATMENT DURATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NAILS; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; FOLLOW-UP STUDIES; FRACTURE FIXATION, INTRAMEDULLARY; FRACTURE HEALING; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84905971054     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-013-2963-1     Document Type: Conference Paper

References (31)

1. Audran M, Cortet B, Thomas T. What do we know about atypical femoral fractures? Insights and enigmas. Joint Bone Spine. 2011;78:568-571.
2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-1541. (Pubitemid 26411651)
3. Capeci CM, Tejwani NC. Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am. 2009;91:2556-2561.
4. Chan SS, Rosenberg ZS, Chan K, Capeci C. Subtrochanterica femoral fractures in patients receiving long-term alendronate therapy: imaging features. AJR Am J Roentgenol. 2010;194:1581-1586.
5. Chrischilles EA, Dasbach EJ, Rubenstein LM, Cook JR, Tabor HK, Black DM. The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial. Osteoporos Int. 2001;12:654-660. (Pubitemid 32889166)
6. Das De S, Setiobudi T, Shen L. A rational approach to management of alendronate-related subtrochanteric fractures. J Bone Joint Surg Br. 2010;92:679-686.
7. Dell R, Greene D. Is osteoporosis diseases management cost effective? Curr Osteoporos Rep. 2010;8:49-55.
8. Egol KA, Park JH, Prensky C, Rosenberg ZS, Peck V, Tejwani NC. Surgical treatment improves clinical and functional outcomes for patients who sustain incomplete bisphosphonaterelated femur fractures. J Orthop Trauma. 2014 Sep 14 [Epub ahead of print].
9. Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004;19:1259-1269. (Pubitemid 41094366)
10. Girgis CM, Seibel MJ. Guilt by association? Examining the role of bisphosphonate therapy in the development of atypical femur fractures. Bone. 2011;48:963-965.
11. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2010;47:169-180.
12. Hollick R, Reid D. Role of bisphosphonates in the management of postmenopausal osteoporosis: an update on recent safety anxieties. Menopause Int. 2011;17:66-72.
13. Hunsaker FG, Cioffi DA, Amadio PC, Wright JG, Caughlin B. The American Academy of Orthopaedic Surgeons outcomes instruments: normative values from the general population. J Bone Joint Surg Am. 2002;84:208-215. (Pubitemid 37127481)
14. Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Safety. 2009;32:775-785.
15. Johnell O, Kanis J. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726-1733. (Pubitemid 44607392)
16. Kanis JA. Assessment of Osteoporosis at the Primary Health-Care Level, WHO Technical Report. Sheffield, UK:WHO Scientific Group,World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield; 2007.
17. Koval KJ, Zuckerman JD, eds. Fractures in the Elderly. New York, NY, USA: Lippincott-Raven Publishers; 1998.
18. Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MC, Lorich DG, Lane JM. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;20:1353-1362.
19. Li J, Mashiba T, Burr D. Bisphosphonate treatment suppresses not only stochnastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int. 2001;69:281-286. (Pubitemid 33140938)
20. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613-620. (Pubitemid 30174014)
21. Mashiba T, Turner C, Hirano T, Forwood M, Johnston C, Burr D. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone. 2001;28:524-531. (Pubitemid 32416465)
22. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346-350. (Pubitemid 351630250)
23. Nieves JW, Cosman F. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep. 2010;8:34-39.
24. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-1301. (Pubitemid 40463979)
25. Rosenberg ZS, La Rocca Vieira R, Chan SS, Babb J, Akyol Y, Rybak LD, Moore S, Bencardino JT, Peck V, Tejwani NC, Egol KA. Bisphosphonate-related complete atypical subtrochanteric femoral fractures: diagnostic utility of radiography. AJR Am J Roentgenol. 2011;197:954-960.
26. Sellmeyer DE. Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA. 2010;304:1480-1484.
27. Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res. 2009;24:1736-1740.
28. Wang K, Moaveni A, Dowrick A, Liew S. Alendronate-associated femoral insufficiency fractures and femoral stress reactions. J Orthop Surg (Hong Kong). 2011;19:89-92.
29. Watts N, Diab D. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555-1565.
30. Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma. 2011;71:186-190.
31. Yoon RS, Hwang JS, Beebe KS. Long-term bisphosphonate usage and subtrochanteric insufficiency fractures. J Bone Joint Surg Br. 2011;93:1289-1295.